176 related articles for article (PubMed ID: 19525472)
1. Kinetic analysis of 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) in head and neck cancer patients before and early after initiation of chemoradiation therapy.
Menda Y; Boles Ponto LL; Dornfeld KJ; Tewson TJ; Watkins GL; Schultz MK; Sunderland JJ; Graham MM; Buatti JM
J Nucl Med; 2009 Jul; 50(7):1028-35. PubMed ID: 19525472
[TBL] [Abstract][Full Text] [Related]
2. Investigation of the pharmacokinetics of 3'-deoxy-3'-[18F]fluorothymidine uptake in the bone marrow before and early after initiation of chemoradiation therapy in head and neck cancer.
Menda Y; Ponto LL; Dornfeld KJ; Tewson TJ; Watkins GL; Gupta AK; Anderson C; McGuire S; Schultz MK; Sunderland JJ; Graham MM; Buatti JM
Nucl Med Biol; 2010 May; 37(4):433-8. PubMed ID: 20447554
[TBL] [Abstract][Full Text] [Related]
3. Kinetic modeling of 3'-deoxy-3'-18F-fluorothymidine for quantitative cell proliferation imaging in subcutaneous tumor models in mice.
Kim SJ; Lee JS; Im KC; Kim SY; Park SA; Lee SJ; Oh SJ; Lee DS; Moon DH
J Nucl Med; 2008 Dec; 49(12):2057-66. PubMed ID: 18997037
[TBL] [Abstract][Full Text] [Related]
4. Kinetic analysis of 3'-deoxy-3'-fluorothymidine PET studies: validation studies in patients with lung cancer.
Muzi M; Vesselle H; Grierson JR; Mankoff DA; Schmidt RA; Peterson L; Wells JM; Krohn KA
J Nucl Med; 2005 Feb; 46(2):274-82. PubMed ID: 15695787
[TBL] [Abstract][Full Text] [Related]
5. 18F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients.
Troost EG; Vogel WV; Merkx MA; Slootweg PJ; Marres HA; Peeters WJ; Bussink J; van der Kogel AJ; Oyen WJ; Kaanders JH
J Nucl Med; 2007 May; 48(5):726-35. PubMed ID: 17475960
[TBL] [Abstract][Full Text] [Related]
6. Stability of 3'-deoxy-3'-[18F]fluorothymidine standardized uptake values in head and neck cancer over time.
Boles Ponto LL; Menda Y; Dornfeld K; Tewson TJ; Watkins GL; Sunderland J; Graham MM; Buatti J
Cancer Biother Radiopharm; 2010 Jun; 25(3):361-3. PubMed ID: 20578842
[TBL] [Abstract][Full Text] [Related]
7. Kinetics of 3'-deoxy-3'-18F-fluorothymidine during treatment monitoring of recurrent high-grade glioma.
Schiepers C; Dahlbom M; Chen W; Cloughesy T; Czernin J; Phelps ME; Huang SC
J Nucl Med; 2010 May; 51(5):720-7. PubMed ID: 20395318
[TBL] [Abstract][Full Text] [Related]
8. Can 3'-Deoxy-3'-((18)F) Fluorothymidine Out Perform 2-Deoxy-2-((18)F) Fluoro-D-Glucose Positron Emission Tomography/Computed Tomography in the Diagnosis of Cervical Lymphadenopathy in Patients With Oral/Head and Neck Cancer?
Schaefferkoetter JD; Carlson ER; Heidel RE
J Oral Maxillofac Surg; 2015 Jul; 73(7):1420-8. PubMed ID: 25869746
[TBL] [Abstract][Full Text] [Related]
9. Early reduction in tumour [18F]fluorothymidine (FLT) uptake in patients with non-small cell lung cancer (NSCLC) treated with radiotherapy alone.
Trigonis I; Koh PK; Taylor B; Tamal M; Ryder D; Earl M; Anton-Rodriguez J; Haslett K; Young H; Faivre-Finn C; Blackhall F; Jackson A; Asselin MC
Eur J Nucl Med Mol Imaging; 2014 Apr; 41(4):682-93. PubMed ID: 24504503
[TBL] [Abstract][Full Text] [Related]
10. Changes in (18)F-fluorothymidine and (18)F-fluorodeoxyglucose positron emission tomography imaging in patients with head and neck cancer treated with chemoradiotherapy.
Hoshikawa H; Mori T; Kishino T; Yamamoto Y; Inamoto R; Akiyama K; Mori N; Nishiyama Y
Ann Nucl Med; 2013 May; 27(4):363-70. PubMed ID: 23378102
[TBL] [Abstract][Full Text] [Related]
11. Reproducibility of quantitative 18F-3'-deoxy-3'-fluorothymidine measurements using positron emission tomography.
de Langen AJ; Klabbers B; Lubberink M; Boellaard R; Spreeuwenberg MD; Slotman BJ; de Bree R; Smit EF; Hoekstra OS; Lammertsma AA
Eur J Nucl Med Mol Imaging; 2009 Mar; 36(3):389-95. PubMed ID: 18931838
[TBL] [Abstract][Full Text] [Related]
12. Histopathologic validation of 3'-deoxy-3'-18F-fluorothymidine PET in squamous cell carcinoma of the oral cavity.
Troost EG; Bussink J; Slootweg PJ; Peeters WJ; Merkx MA; van der Kogel AJ; Oyen WJ; Kaanders JH
J Nucl Med; 2010 May; 51(5):713-9. PubMed ID: 20395329
[TBL] [Abstract][Full Text] [Related]
13. Kinetic modeling of 3'-deoxy-3'-fluorothymidine in somatic tumors: mathematical studies.
Muzi M; Mankoff DA; Grierson JR; Wells JM; Vesselle H; Krohn KA
J Nucl Med; 2005 Feb; 46(2):371-80. PubMed ID: 15695799
[TBL] [Abstract][Full Text] [Related]
14. Reproducibility of the kinetic analysis of 3'-deoxy-3'-[(18)F]fluorothymidine positron emission tomography in mouse tumor models.
Choi SJ; Kim SY; Kim SJ; Lee JS; Lee SJ; Park SA; Lee SJ; Yun SC; Im KC; Oh SJ; Kim SW; Kim JS; Ryu JS; Moon DH
Nucl Med Biol; 2009 Oct; 36(7):711-9. PubMed ID: 19720283
[TBL] [Abstract][Full Text] [Related]
15. Usefulness of 3'-deoxy-3'-18F-fluorothymidine PET for predicting early response to chemoradiotherapy in head and neck cancer.
Kishino T; Hoshikawa H; Nishiyama Y; Yamamoto Y; Mori N
J Nucl Med; 2012 Oct; 53(10):1521-7. PubMed ID: 22872738
[TBL] [Abstract][Full Text] [Related]
16. Kinetic analysis of 3'-deoxy-3'-18F-fluorothymidine in patients with gliomas.
Muzi M; Spence AM; O'Sullivan F; Mankoff DA; Wells JM; Grierson JR; Link JM; Krohn KA
J Nucl Med; 2006 Oct; 47(10):1612-21. PubMed ID: 17015896
[TBL] [Abstract][Full Text] [Related]
17. 18F-FLT PET during radiotherapy or chemoradiotherapy in head and neck squamous cell carcinoma is an early predictor of outcome.
Hoeben BA; Troost EG; Span PN; van Herpen CM; Bussink J; Oyen WJ; Kaanders JH
J Nucl Med; 2013 Apr; 54(4):532-40. PubMed ID: 23345303
[TBL] [Abstract][Full Text] [Related]
18. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG.
Chen W; Cloughesy T; Kamdar N; Satyamurthy N; Bergsneider M; Liau L; Mischel P; Czernin J; Phelps ME; Silverman DH
J Nucl Med; 2005 Jun; 46(6):945-52. PubMed ID: 15937304
[TBL] [Abstract][Full Text] [Related]
19. 3'-deoxy-3'-[¹⁸F]fluorothymidine PET quantification of bone marrow response to radiation dose.
McGuire SM; Menda Y; Boles Ponto LL; Gross B; Buatti J; Bayouth JE
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):888-93. PubMed ID: 21300484
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous positron emission tomography (PET) assessment of metabolism with ¹⁸F-fluoro-2-deoxy-d-glucose (FDG), proliferation with ¹⁸F-fluoro-thymidine (FLT), and hypoxia with ¹⁸fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study.
Vera P; Bohn P; Edet-Sanson A; Salles A; Hapdey S; Gardin I; Ménard JF; Modzelewski R; Thiberville L; Dubray B
Radiother Oncol; 2011 Jan; 98(1):109-16. PubMed ID: 21056487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
